Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Account Payables (2024 - 2025)

Prelude Therapeutics' Change in Account Payables history spans 2 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 29.78% year-over-year to $1.3 million; the TTM value through Dec 2025 reached -$3.9 million, down 218.55%, while the annual FY2025 figure was -$3.9 million, 218.55% down from the prior year.
  • Change in Account Payables for Q4 2025 was $1.3 million at Prelude Therapeutics, up from -$2.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.8 million in Q4 2024 and bottomed at -$2.4 million in Q3 2025.